flotetuzumab + ruxolitinib

**flotetuzumab + ruxolitinib** is an investigational combination therapy currently being studied for relapsed/refractory acute myeloid leukemia (AML), particularly to mitigate cytokine release syndrome (CRS) during flotetuzumab treatment[1][5]. Flotetuzumab is a bispecific DART (dual-affinity re-targeting) antibody that engages both CD123 (on AML blasts) and CD3 (on T-cells), redirecting T-cell cytotoxicity toward AML cells[5]. Ruxolitinib is a Janus kinase (JAK) 1/2 inhibitor, FDA-approved for myelofibrosis, polycythemia vera, and graft-versus-host disease[2][6], and is used prophylactically in this combination to reduce the frequency and severity of CRS during flotetuzumab immunotherapy[1][5].

Other names

flotetuzumab + ruxolitinibFLZ + RUX